POLB vs. TRX, REDX, ETX, AREC, C4XD, HEMO, SBTX, ONC, OBD, and DEST
Should you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Tissue Regenix Group (TRX), Redx Pharma (REDX), e-therapeutics (ETX), Arecor Therapeutics (AREC), C4X Discovery (C4XD), Hemogenyx Pharmaceuticals (HEMO), SkinBioTherapeutics (SBTX), Oncimmune (ONC), Oxford BioDynamics (OBD), and Destiny Pharma (DEST). These companies are all part of the "biotechnology" industry.
Tissue Regenix Group (LON:TRX) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk, community ranking and earnings.
Tissue Regenix Group has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Poolbeg Pharma has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500.
50.1% of Tissue Regenix Group shares are held by institutional investors. Comparatively, 6.1% of Poolbeg Pharma shares are held by institutional investors. 48.1% of Tissue Regenix Group shares are held by company insiders. Comparatively, 21.5% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Poolbeg Pharma's average media sentiment score of 0.00 equaled Tissue Regenix Group'saverage media sentiment score.
Tissue Regenix Group has higher revenue and earnings than Poolbeg Pharma. Tissue Regenix Group is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.
Poolbeg Pharma has a net margin of 0.00% compared to Poolbeg Pharma's net margin of -5.81%. Poolbeg Pharma's return on equity of -5.55% beat Tissue Regenix Group's return on equity.
Tissue Regenix Group received 162 more outperform votes than Poolbeg Pharma when rated by MarketBeat users.
Summary
Tissue Regenix Group beats Poolbeg Pharma on 7 of the 11 factors compared between the two stocks.
Get Poolbeg Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Poolbeg Pharma Competitors List
Related Companies and Tools
